Optum guides providers through important upcoming formulary updates
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
January 24, 2017 – The FDA announced the discontinuation of Enjuvia (synthetic conjugated estrogens, B) due to business reasons.
Download PDF
Return to publications
